Effects of calcitriol on bone mineral density in patients treated with esomeprazole.
Study Goal
The researchers aimed to determine whether calcitriol supplementation could improve bone mineral density (BMD) in patients on esomeprazole therapy.
Results Summary
The study found no significant improvement in BMD with calcitriol supplementation, though calcium levels were slightly higher in the supplemented group. No significant differences were observed in CTX or ALP levels between groups.
Population
Patients with gastrointestinal ulcerations on esomeprazole therapy.
Effective Dosage
Calcitriol 2.5 μg once daily.
Duration
Approximately 10.6 days.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Proton pump inhibitor (PPI) | decrease | bone mineral density (BMD) | - | - | increases the risk of decrease | #1 |
esomeprazole (20 mg/qd) | increase | BMD T score | participants with gastrointestinal ulcerations in the controlled group | -1.25 ± 0.08 versus -1.28 ± 0.06 | slightly increased | #2 |
esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd) | no change | BMD T score | participants with gastrointestinal ulcerations in the supplemented group | -1.25 ± 0.05 versus -1.26 ± 0.03 | no change | #3 |
esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd) | increase | calcium level | participants with gastrointestinal ulcerations in the supplemented group | 2.05 ± 0.03 mmol/L versus 2.01 ± 0.05 mmol/L | slightly higher | #4 |
esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd) | no change | CTX | participants with gastrointestinal ulcerations in the supplemented group | 366.57 ± 43.71 pg/mL versus 373.15 ± 50.23 pg/mL | no significant differences | #5 |
esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd) | no change | ALP | participants with gastrointestinal ulcerations in the supplemented group | 50.47 ± 9.32 U/L versus 52.23 ± 10.45 U/L | no significant differences | #6 |
calcitriol supplement | no change | BMD changes | Patients with gastrointestinal ulcerations with esomeprazole therapy | - | showed no efficacy | #7 |
CONTEXT: Proton pump inhibitor (PPI) increases the risk of decrease in bone mineral density (BMD). However, whether calcitrol improves this situation is unknown. OBJECTIVE: The current study investigates the effects of calcitriol on BMD in patients with esomeprazole therapy. MATERIALS AND METHODS: Three hundred and eighty-six participants with gastrointestinal ulcerations were enrolled and randomly assigned into controlled and supplemented groups. Participants in the controlled group were prescribed esomeprazole (20 mg/qd), while the supplemented group was prescribed esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd). BMD, serum levels of calcium, carboxy-terminal collagen crosslinks (CTX), and alkaline-phosphatase (ALP) were assessed. RESULTS: (1) No significant between-group difference of age, gender, smoking, previous glucocorticoid use and hemoglobin level was found; (2) after 10.6 ± 0.8 d of PPI therapy, BMD T score in the controlled group was slightly increased compared with initial (-1.25 ± 0.08 versus -1.28 ± 0.06, p = 0.084), while there was no change in the supplemented group (-1.25 ± 0.05 versus -1.26 ± 0.03, p = 0.308); (3) during study termination, calcium level in the supplemented group was slightly higher than the controlled group (2.05 ± 0.03 mmol/L versus 2.01 ± 0.05 mmol/L, p = 0.073), while no significant differences of CTX (366.57 ± 43.71 pg/mL versus 373.15 ± 50.23 pg/mL, p = 0.036) and ALP were found among these two groups (50.47 ± 9.32 U/L versus 52.23 ± 10.45 U/L, p = 0.075). CONCLUSION: Patients with gastrointestinal ulcerations with esomeprazole therapy, calcitriol supplement showed no efficacy on BMD changes.